share_log
Reuters ·  Apr 26 09:55
Johnson & Johnson Receives Positive Chmp Opinion for Rybrevant®▼ (Amivantamab) in Combination With Chemotherapy for the First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer With Activating Egfr Exon 20 Insertion Mutations
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment